COVID-19 and hypertension: Is there a role for dsRNA and activation of Toll-like receptor 3?

Vascul Pharmacol. 2021 Oct:140:106861. doi: 10.1016/j.vph.2021.106861. Epub 2021 Apr 22.

Abstract

The virus responsible for the coronavirus disease of 2019 (COVID-19) is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidences suggest that COVID-19 could trigger cardiovascular complications in apparently healthy patients. Coronaviruses are enveloped positive-strand RNA viruses acting as a pathogen-associated molecular pattern (PAMP)/ danger-associated molecular patterns (DAMP). Interestingly, Toll-like receptor (TLR) 3 recognize both PAMPs DAMPs and is activated by viral double-stranded RNA (dsRNA) leading to activation of TIR receptor domain-containing adaptor inducing IFN-β (TRIF) dependent pathway. New evidence has shown a link between virus dsRNA and increased BP. Hence, we hypothesize that COVID-19 infection may be over activating the TLR3 through dsRNA, evoking further damage to the patients, leading to vascular inflammation and increased blood pressure, favoring the development of several cardiovascular complications, including hypertension.

Keywords: COVID-19; Hypertension; TLR3; dsRNA.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • COVID-19 / genetics*
  • COVID-19 / pathology*
  • Humans
  • Hypertension / genetics*
  • Hypertension / pathology
  • Hypertension / virology
  • Mice
  • RNA, Double-Stranded / genetics*
  • SARS-CoV-2 / pathogenicity
  • Signal Transduction / genetics
  • Toll-Like Receptor 3 / genetics*

Substances

  • RNA, Double-Stranded
  • Toll-Like Receptor 3